Using 23andMe to Reunite Families at the Border Comes With Serious Privacy Risks
By Tonya Riley, Mother Jones [Cites CGS' Marcy Darnovsky] | 06. 22. 2018
On Wednesday, President Donald Trump announced an end to administration’s policy of separating families at the border. But the administration hasn’t figured out how to reunite the parents and children that have already been split apart. A day after Trump’s announcement, Rep. Jackie Speier (D-Calif.) suggested a novel idea: recruit 23andMe, the DNA-testing company, to help separated families find missing relatives. The company itself quickly volunteered its services for the cause. But legal and genetic experts say that the solution might cause more harm than good.
Speier told Buzzfeed News on Thursday that she spoke with executives at 23andMe, which is headquartered in the congresswoman’s district, about providing testing assistance to reunite families at the border. By Thursday evening, 23andMe CEO Anne Wojcicki said that the company “would welcome any opportunity to help” and was “waiting to see the best way to follow up and make it happen.” (23andMe donated $5,000 to Speier’s 2016 campaign.)
“I implore the President, Attorney General Sessions, and HHS Secretary Azar to accept this generous and altruistic offer, particularly in light of the fact that...
Related Articles
By Matthew Weaver, The Guardian | 09.18.2018
The fertility regulator has called for DNA testing websites to warn customers about the risks of uncovering traumatic family secrets and underlying health traits.
Sites such as Ancestry.com, 23andMe and DNA.com offer customers the chance to discover long-lost relatives by...
By Laura Hercher, The New York Times | 09.15.2018
In many ways, Matt Fender, a 32-year-old resident of New York City, is the prototypical 23andMe customer: tech-savvy, educated, a bit of a worrier. But he wasn’t worried last December when he clicked a button to dump all the raw...
In 2004, Voters approved Proposition 71 by nearly 60 percent establishing a $3 billion bond to fund the science of stem cell therapy. As a result, the California Institute for Regenerative Medicine, or CIRM, was created to manage the funds...
By Liz Szabo, The New York Times | 09.11.2018
Facing incurable breast cancer at age 55, MaryAnne DiCanto put her faith in “precision medicine” — in which doctors try to match patients with drugs that target the genetic mutations in their tumors. She underwent repeated biopsies to identify therapies...
